Praxis Precision Medicines PRAX 深 滬
已收盤 04-02 16:00:00 美东时间
310.38
-8.900
-2.79%
華盛通- 最 高321.94
- 今 開308.97
- 成交量 30.02万股
- 最 低 308.505
- 昨 收 319.28
- 總市值 86.44亿
- 52周最高 355.9999
- 市盈率 靜 --
- 換手率 1.08%
- 52周最低 28.79
- 委 比 98.91%
- 總股本 2785.08万
- 歷史最高 914.265
- 量 比 0.62
- 振 幅 4.21%
- 歷史最低 11.85
- 每 手 1
- 風險率 117.06%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Praxis Precision Medicines granted restricted stock unit awards totaling 3,558 shares to 18 new non-executive employees under the 2024 Inducement Plan on April 1, 2026. The awards vest annually over four years and are intended to induce employment with Praxis, as permitted by Nasdaq rules.
04-02 20:01
Apellis Pharmaceuticals, Centessa Pharmaceuticals, Agios Pharmaceuticals And Other Big Stocks Moving Higher On Tuesday
US stocks rise, Dow Jones gains 600+ pts. Apellis Pharma shares surge 136.4% after buyout by Biogen for $41/share. Other gainers incl. Centessa, Annexon, Agios, Fulcrum, Scholar Rock, Alkermes, Wave Life, Perimeter Solutions, Praxis Precision, and Century Aluminum.
03-31 21:57
Praxis Precision Medicines Announces FDA Acceptance and Priority Review of New Drug Application for Relutrigine in Patients with SCN2A and SCN8A DEEs
Praxis Precision Medicines announced the U.S. FDA has accepted for priority review its New Drug Application (NDA) for relutrigine to treat SCN2A and SCN8A developmental and epileptic encephalopathies (DEEs). The FDA set a PDUFA target action date of September 27, 2026. If approved, relutrigine would be the first disease-modifying therapy for these conditions. The NDA is supported by positive results from the EMBOLD study and the drug holds Orphan...
03-30 20:01
Pyxis Oncology Provides Business Update and Reports Fourth Quarter and Full Year 2025 Financial Results
Pyxis Oncology, Inc. reported updates on its lead candidate MICVO, including completion of target enrollment in a Phase 1 monotherapy study for recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC) in the first quarter of 2026. The company also announced updated data expected in mid-2026, which will include patients treated with modified weight-based dosing. Additionally, Pyxis Oncology shared financial results for 2025, includin...
03-23 11:00
Xenon Pharmaceuticals Rallies After Pivotal Data Shows Major Drop In Monthly Seizures
Xenon Pharmaceuticals shares surge after Phase 3 data show strong seizure reduction for azetukalner, with FDA filing planned for 2026.
03-09 21:26
Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Praxis Precision Medicines granted restricted stock unit awards covering 2,931 shares to 14 new non-executive employees under its 2024 Inducement Plan. The awards, granted on March 2, 2026, vest in four equal annual installments and are contingent on continued employment. The company, focused on CNS precision neuroscience, develops therapies for genetic epilepsies and neuronal excitation-inhibition imbalances using its proprietary platforms Cereb...
03-04 21:01
美股大行评级 | 潜在涨幅243.25%！泰利克斯制药获花旗升目标价至22.5美元，维持"买入"评级
今日重点评级关注：花旗：维持Telix Pharmaceuticals"买入"评级，目标价从22美元升至22.5美元；摩根士丹利：维持Vir Biotechnology"超配"评级，目标价从20美元升至24美元
02-25 11:03
美股大行评级 | 潜在涨幅214.14%！HC Wainwright & Co.：Ardelyx获机构升目标价至18美元，维持"买入"评级
今日重点评级关注：HC Wainwright & Co.：维持Ardelyx"买入"评级，目标价从10美元升至18美元；Truist Securities：维持Praxis Precision Medicine"买入"评级，目标价从500美元升至700美元
02-23 08:56
Praxis Precision Medicine Analysts Raise Their Forecasts After Q4 Results
Praxis Precision Medicines, Inc. (NASDAQ:PRAX) reported a wider-than-expected l...
02-21 01:10
Wedbush Maintains Underperform on Praxis Precision Medicine, Raises Price Target to $130
Wedbush analyst Laura Chico maintains Praxis Precision Medicine (NASDAQ:PRAX) with a Underperform and raises the price target from $95 to $130.
02-20 21:24
